Related Experiment Video
Updated: Aug 30, 2025
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
12.1K
Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack
Lorenzo Scalia1, Dario Calderone1, Davide Capodanno1
1Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico "G. Rodolico-San Marco", University of Catania, Catania, Italy.
Expert Review of Clinical Pharmacology
|August 29, 2022
Summary
Antiplatelet therapy is crucial for preventing recurrent non-cardioembolic stroke or transient ischemic attack (TIA). Balancing ischemic risk and bleeding is key, with dual therapy often considered post-event.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Antiplatelet therapy is essential for secondary prevention in non-cardioembolic stroke and transient ischemic attack (TIA).
- Managing these patients involves a critical balance between preventing ischemic events and minimizing major bleeding risks.
Purpose of the Study:
- To review current evidence on antiplatelet therapy for non-cardioembolic stroke or TIA.
- To explore established and emerging antithrombotic strategies in this patient population.
Main Methods:
- Comprehensive literature search of randomized controlled trials (RCTs) on antithrombotic strategies.
- Databases searched include Pubmed/Medline from 1970 to 2022.
Main Results:
- Single antiplatelet therapy (aspirin, clopidogrel) or aspirin-dipyridamole is standard for non-cardioembolic stroke/TIA.
- Short-term dual antiplatelet therapy (aspirin with clopidogrel or ticagrelor) is recommended after acute events.
- Ticagrelor may increase bleeding risk; direct comparison with clopidogrel is lacking.
Conclusions:
- Current guidelines support specific antiplatelet regimens for non-cardioembolic stroke/TIA.
- Dual antiplatelet therapy offers short-term benefits post-event, but bleeding risk requires consideration.
- Future research may explore dual-pathway inhibition, including factor XI inhibitors, for enhanced stroke prevention.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
619
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
619
01:27Peripheral Artery Disease III: Interprofessional Care
27
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
27
01:29Venous Thrombosis III: Interprofessional Care
18
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
01:27Coronary Artery Disease V: Interprofessional Care
24
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
24
01:28Acute Coronary Syndrome IV: Interprofessional Care
22
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
22
01:22Formation of the Platelet Plug
7.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.0K